Education
About Us
Working with TipRanks
Follow Us
Propanc Biopharma (PPCB)
NASDAQ:PPCB
PPCB Stock Chart & Stats
$0.22
$0.00(0.00%)
At close: 4:00 PM EST
$0.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.11 - $11.00
Previous CloseN/A
Volume127.03K
Average Volume (3M)400.33K
Market Cap
$1.88M
Enterprise Value$3.01M
Total Cash (Recent Filing)$561.24K
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta-1.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,859,280
10 Day Avg. Volume553,394
30 Day Avg. Volume400,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-40.64
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue100.51
Enterprise Value/Gross Profit22.77K
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low reported debt (debt-to-equity ~0.01) gives Propanc structural financial flexibility and reduces near-term insolvency risk. For a pre-commercial biotech, low leverage lowers fixed obligations, preserving optionality to time financing and partnerships to advance R&D over the next several quarters.
Experienced Scientific LeadershipAdding Dr. Ralf Brant, a veteran with decades in drug discovery and >50 compounds advanced to clinic, strengthens scientific governance and translational expertise. This improves long-term R&D decisionmaking, trial design and partner credibility—key for advancing preclinical assets into clinical stages.
Promising Lead Preclinical Data (PRP)PRP's reported preclinical effects—high tumor growth inhibition, reduced fibrosis, and activity versus cancer stem cells—suggest differentiated mechanism and combination potential with chemo. Structurally, robust preclinical efficacy increases probability of partnerships, licensing interest and clinical development pathways.
Bears Say
Minimal Revenue / Pre-commercialWith essentially no commercial revenue (~$0.03M TTM) and prior years showing no sales, the company remains pre-commercial. Over the medium term this means operations must be funded externally, and long-term viability depends on successful clinical progression rather than current operating performance.
Sustained Negative Cash FlowConsistent negative operating and free cash flow (~-$3.1M TTM) indicates ongoing cash burn and inability to self-fund development. Structurally, this forces recurring equity or partnership financings, increasing dilution risk and potentially slowing R&D timelines if capital markets tighten.
Nasdaq Listing Noncompliance RiskNasdaq minimum bid-price noncompliance creates delisting risk and could materially hinder liquidity and access to public capital. Over months, this structural issue can raise financing costs, reduce attractiveness to partners, and impair ability to offer equity incentives essential for small biotech execution.
Propanc Biopharma News
PPCB FAQ
What was Propanc Biopharma’s price range in the past 12 months?
Propanc Biopharma lowest stock price was $0.11 and its highest was $11.00 in the past 12 months.
What is Propanc Biopharma’s market cap?
Propanc Biopharma’s market cap is $1.88M.
When is Propanc Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Propanc Biopharma’s earnings last quarter?
Currently, no data Available
Is Propanc Biopharma overvalued?
According to Wall Street analysts Propanc Biopharma’s price is currently Overvalued.
Does Propanc Biopharma pay dividends?
Propanc Biopharma does not currently pay dividends.
What is Propanc Biopharma’s EPS estimate?
Propanc Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Propanc Biopharma have?
Propanc Biopharma has 15,859,280 shares outstanding.
What happened to Propanc Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Propanc Biopharma?
Currently, no hedge funds are holding shares in PPCB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Technical Analysis
Verrica Pharmaceuticals
―
―
―
Barinthus Biotherapeutics
―
Telomir Pharmaceuticals, Inc.
―